COPD – GSK 224295

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.

Inclusion Criteria:

  • Male or eligible female participants
  • Eosinophilic phenotype measured using Blood Eosinophil Count (BEC)
  • Moderate to severe COPD, defined as
    • A clinically documented history of COPD for at least 1 year
    • A post-salbutamol Forced expiratory volume in one second (FEV1)/Forced vital capacity (FVC) ratio of less than (<)0.70 and a post-salbutamol FEV1 greater than (>)30 percent (%) and <80% predicted normal values
  • Elevated risk for exacerbations
  • Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.

View Study on ClinicalTrials.gov

Trial Interest Form

Locations

Clarkston Medical Group

5701 Bow Pointe Drive
Suites 100 & 105
Clarkston, Michigan